Sun Pharmaceutical
Sun Pharmaceutical exhibits strong financial health and profitability, driven by healthy operating margins and robust interest coverage. While growth metrics show moderate expansion, the company's efficient cash flow generation and prudent capital allocation contribute positively to long-term value creation. However, current valuation metrics indicate the stock is trading at a premium compared to its calculated intrinsic value, suggesting a limited margin of safety for potential business analysis.
Business Performance (CAGR)
Valuation Snapshot
Financial Health
Profitability Metrics
Cash Flow Intelligence
Intrinsic Value
PremiumEstimated Intrinsic Value & DCF Fair Value are available with Premium plans.
AI Business Verdict
Sun Pharmaceutical exhibits strong financial health and operational efficiency, contributing to solid profitability and consistent book value growth. While its business quality and capital allocation are commendable, the current market valuation appears to outpace its intrinsic value, implying a premium that warrants careful consideration for long-term value creation.
- Exceptional financial strength with very low debt and high interest coverage.
- Robust operating and net profit margins demonstrating efficient operations.
- Strong cash flow generation from operations, with OCF exceeding PAT.
- Consistent growth in book value, indicating effective capital reinvestment.
Balance Sheet
Sun Pharmaceutical shows a strong balance sheet with healthy liquidity, moderate leverage and steady equity compounding.
Capacity to fund growth, withstand downturns and return capital.
- Sun Pharmaceutical shows a strong balance sheet with healthy liquidity, moderate leverage and steady equity compounding.
- Net cash position — debt fully covered by cash & investments
- Large cash & investment reserves
- Very low leverage with net cash balance
- High interest coverage
- Long working capital cycle
- Large 'other assets' bucket — investigate composition